Revista Colombiana de Reumatología (English Edition)最新文献

{"title":"Systemic sclerosis and interstitial lung disease: From pathogenesis, to screening, diagnosis, and classification","authors":"Helena Codes ,&nbsp;Aslihan Avanoglu Guler ,&nbsp;Corrado Campochiaro ,&nbsp;Marco Matucci Cerinic ,&nbsp;Ivan Castellvi","doi":"10.1016/j.rcreue.2024.05.002","DOIUrl":"https://doi.org/10.1016/j.rcreue.2024.05.002","url":null,"abstract":"<div><p>Interstitial lung disease (ILD) is a common and potentially devastating complication of systemic sclerosis (SSc), a chronic autoimmune disorder characterized by fibrosis and vascular abnormalities. The association between SSc and ILD underscores the intricate interplay between immune dysregulation, vasculopathy, and tissue fibrosis. This review provides a comprehensive overview of the immunological, clinical, and radiological features of ILD in the context of SSc. It highlights the diverse spectrum of ILD patterns observed in SSc patients, ranging from non-specific interstitial pneumonia to usual interstitial pneumonia. The intricate pathogenic mechanisms linking SSc and ILD involve aberrant immune responses, endothelial dysfunction, profibrotic cytokine signaling, and genetic factors. Immunological alterations, diagnostic challenges, and prognostic implications are discussed, underscoring the need for multidisciplinary management strategies. By elucidating the complex relationship between SSc and ILD, this review aims to contribute to a deeper understanding of the underlying mechanisms and facilitate the development of interdisciplinary interventions for improved patient outcomes.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S54-S66"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141090954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The lung as a target and as an initiator of rheumatoid arthritis-associated immunity: Implications for interstitial lung disease","authors":"Malena Loberg Haarhaus,&nbsp;Lars Klareskog","doi":"10.1016/j.rcreue.2023.09.002","DOIUrl":"https://doi.org/10.1016/j.rcreue.2023.09.002","url":null,"abstract":"<div><p>Interstitial lung disease (ILD) is a serious extra-articular co-morbidity in rheumatoid arthritis (RA) patients and accounts for a substantial part of the increased mortality in RA. In this review, we describe how environmental and lifestyle factors interact with genetic variants in the HLA genetic locus in triggering RA-specific antibodies against post-translationally modified, mainly citrullinated proteins (ACPA), which are associated with an increased risk of ILD. The same environmental risk factors, i.e. exposure to noxious agents such as smoke to the lungs contribute additionally to the emergence of RA ILD as does long-lasting high disease activity and an additional ILD-specific genetic risk variant related to mucus formation (MUC5B). Options for prevention and therapy of RA ILD resulting from this so far incomplete knowledge of its pathophysiology are expanding. The most obvious option is to address modifiable environmental risk factors, such as smoking and exposure to other noxious agents affecting the lungs. The second option is to reduce the inflammatory activity of RA; here different anti-rheumatic therapies appear to have differential effects on ILD development. The third and novel option is to use anti-fibrotic therapy which may reduce the development of RA ILD but has not yet been shown to revert existing fibrosis. The main conclusion concerning the clinical handling of RA ILD is therefore an early awareness of the risk for RA ILD combined with active measures to reduce modifiable environmental/lifestyle factors and use optimal anti-rheumatic therapies for early and sustained reduction of disease activity. These actions should be combined with a preparedness to use anti-fibrotic therapy for patients at high risk for ILD despite previous risk reduction efforts.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S74-S81"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141090956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequential approach to interstitial lung disease: An autoimmune perspective","authors":"Camila Borda Samper ,&nbsp;Néstor Fabián Correa-González ,&nbsp;Carlos Andrés Celis Preciado ,&nbsp;Santiago Bernal-Macías ,&nbsp;Juan Sebastián Sierra ,&nbsp;Daniel G. Fernández-Ávila","doi":"10.1016/j.rcreue.2023.10.006","DOIUrl":"https://doi.org/10.1016/j.rcreue.2023.10.006","url":null,"abstract":"<div><p>Interstitial lung disease occurs with high frequency as an initial or late manifestation of multiple rheumatic diseases, including systemic sclerosis, idiopathic inflammatory myopathies, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's syndrome and antineutrophil cytoplasmic antibody-associated vasculitis. Thus, the rheumatologist must be clear about certain concepts of pneumology, including the evaluation of lung function tests, the approach to radiological patterns observed on high-resolution computed tomography of the chest, and concepts such as interstitial pneumonia with autoimmune features. In this article, we present our approach to patients with interstitial lung disease, in whom an autoimmune etiology is suspected. We propose a sequential diagnostic strategy, recognizing the importance of the multidisciplinary team and including the autoimmune perspective with emphasis on clinical and serological domains. Other diagnostic tools such as capillaroscopy and minor salivary gland biopsy are also considered. We also take a critical look at the latest guidelines for progressive pulmonary fibrosis, since it is essential that the rheumatologist understands these concepts that are vital in a multidisciplinary team.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S94-S109"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141090991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review","authors":"Samuel D. Good ,&nbsp;Jeffrey A. Sparks ,&nbsp;Elizabeth R. Volkmann","doi":"10.1016/j.rcreue.2024.05.001","DOIUrl":"https://doi.org/10.1016/j.rcreue.2024.05.001","url":null,"abstract":"<div><p>Interstitial lung disease (ILD) is a common and serious manifestation of autoimmune rheumatic diseases. While the prevalence of ILD differs among the individual autoimmune rheumatic diseases, ILD remains an important cause of morbidity and mortality in systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, primary Sjögren's disease, rheumatoid arthritis, and idiopathic inflammatory myositis. The present review summarizes recent literature on autoimmune-associated ILD with a focus on screening and monitoring for ILD progression. Reflecting on the currently available evidence, the authors propose a guideline for monitoring for progression in patients with newly diagnosed autoimmune-associated ILD. This review also highlights clinical and biological predictors of progressive pulmonary fibrosis and describes opportunity for further study in the rapidly evolving area of rheumatology and pulmonology.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S3-S14"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141091040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease","authors":"Scott M. Matson ,&nbsp;Joyce S. Lee","doi":"10.1016/j.rcreue.2023.07.005","DOIUrl":"https://doi.org/10.1016/j.rcreue.2023.07.005","url":null,"abstract":"<div><p>Rheumatoid arthritis associated interstitial lung disease (RA-ILD) has significant clinical impact on patients due to increased morbidity and mortality. Understanding the progression of ILD in patients with RA from when asymptomatic to clinical progression and the clinical, genetic, and novel markers associated with disease progression is an important step in altering the natural history of ILD in patients with RA. We review the natural history and epidemiology of RA-ILD, with a focus on Latin-American epidemiology in RA-ILD. Additionally, we discuss unique features of RA-ILD compared to other forms of ILD, early disease detection, and current concepts in treatment.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S26-S34"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141091042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement of health-related quality of life in patients with interstitial lung disease and autoimmune diseases","authors":"Claudia Mora ,&nbsp;Alirio Rodrigo Bastidas Goyes ,&nbsp;Lina Paola Fajardo Muriel ,&nbsp;Cristian Felipe Rodríguez Yasno","doi":"10.1016/j.rcreue.2023.08.001","DOIUrl":"https://doi.org/10.1016/j.rcreue.2023.08.001","url":null,"abstract":"<div><p>Autoimmune diseases comprise a wide and diverse group of diseases, each with its own specific complications, and with common complications such as pulmonary involvement. Lung involvement is extensive and one of its complications is interstitial lung disease, which varies widely within each of the autoimmune diseases. Health-related quality of life is defined as all those aspects that reflect the impact of the disease and the perception of disability and daily functionality of the patient. Even though this concept is subjective, health researchers have sought to define it to serve as a tool in the evaluation of interventions in subjects with different types of pathologies, so much so that it has become a main outcome in program evaluation and clinical research. To date, we are not aware of tools designed with the objective of measuring quality of life specifically in lung involvement due to interstitial lung disease related to autoimmune diseases. The objective of this review will be to further explore the available information on the measurement of quality of life in these patients.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S67-S73"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141090955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colombian rheumatology in the Latin American context","authors":"Thalía Pinilla ,&nbsp;Isabella Lacouture ,&nbsp;Sofía de los Ángeles Acosta Rivas ,&nbsp;Diego Rosselli","doi":"10.1016/j.rcreue.2023.03.005","DOIUrl":"10.1016/j.rcreue.2023.03.005","url":null,"abstract":"","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 2","pages":"Page 280"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141638629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibromyalgia and associated factors in patients with axial spondyloarthritis: The effect of fibromyalgia on disease activity","authors":"İpek Türk ,&nbsp;Mehmet Ali Aşık ,&nbsp;Şerife Şeyda Zengin Acemoğlu ,&nbsp;Gizem Varkal ,&nbsp;İlker Ünal","doi":"10.1016/j.rcreue.2022.10.004","DOIUrl":"10.1016/j.rcreue.2022.10.004","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>The aim of this study was to investigate the frequency of fibromyalgia (FM) in axial spondyloarthritis (ax-SpA) patients using the current FM diagnostic criteria (2016 Revised Fibromyalgia Diagnostic Criteria). Additionally, we aimed to investigate the relationship between FM severity and disease activity, functional status, and quality of life (QoL).</p></div><div><h3>Materials and methods</h3><p>Disease activity, functional disability and QoL were evaluated. FM severity was measured with the fibromyalgia impact questionnaire (FIQ).</p></div><div><h3>Results</h3><p>One hundred and three patients with ax-SpA (55.3% female; mean age 44<!--> <!-->±<!--> <!-->10.85 years) were included. FM was detected in 49.5% of the patients. While FM was detected in 71% of patients with a history of peripheral arthritis, FM was present in 59.2% of patients without (<em>p</em> = 0.009). FM-ax-SpA patients showed higher disease activity except for C-reactive protein; functional status and QoL were statistically worse in patients with FM-SpA. Significant positive correlations were found between FIQ and disease activity, functional disability and QoL (<em>p</em> <!-->&lt;<!--> <!-->.001).</p></div><div><h3>Conclusions</h3><p>The most effective features associated with the presence of FM were detected as gender and a history of peripheral arthritis. Presence of FM may cause an overestimation of disease activity, FM severity correlates with disease activity.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 2","pages":"Pages 159-165"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141638631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial lung disease in primary Sjögren's syndrome","authors":"Santiago Auteri ,&nbsp;Anastasia Secco","doi":"10.1016/j.rcreue.2023.10.007","DOIUrl":"https://doi.org/10.1016/j.rcreue.2023.10.007","url":null,"abstract":"<div><p>Interstitial lung disease is a common complication of Sjögren's syndrome that can occur at diagnosis or during follow-up. To detect it, complete pulmonary function studies should be performed, including spirometry, measurement of lung volumes, and DLCO, with the latter being the most sensitive parameter for detecting the presence of the disease. High-resolution computed tomography is essential for the study. Sixty percent of patients present a single tomographic pattern, with non-specific interstitial pneumonia being the most frequent pattern, followed by usual interstitial pneumonia pattern. Mortality is high, being higher in those with lower forced vital capacity, lower DLCO, and higher fibrosis score on chest computed tomography. Currently, there are two international guidelines for the treatment of pulmonary manifestations of Sjögren, but recommendations are based on low-quality scientific evidence. A stepwise approach is suggested, initially with glucocorticoids, then immunosuppressants, and in refractory or severe cases, considering other agents such as rituximab. The use of antifibrotic medication is recommended in patients who develop progressive pulmonary fibrosis as defined by current criteria. It is important to bear in mind that although non-specific interstitial pneumonia is considered a pattern where inflammation predominates, there may be progression to progressive pulmonary fibrosis in some cases. Lung transplantation and oxygen therapy may be options for selected patients. The relevance of an interdisciplinary team approach to achieve adequate diagnosis and treatment of patients is highlighted.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S123-S131"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141090992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive pulmonary fibrosis associated autoimmune diseases: Systematic review of the literature","authors":"Luis Javier Cajas Santana ,&nbsp;Diana Rocío Gil Calderón ,&nbsp;Manuela Rubio Rivera ,&nbsp;José Alex Yate ,&nbsp;Javier Leonardo Galindo","doi":"10.1016/j.rcreue.2023.09.003","DOIUrl":"https://doi.org/10.1016/j.rcreue.2023.09.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Connective tissue disease-related interstitial lung disease (CTD-ILD) accounts for 30% of all cases of ILD. Some patients progress and develop progressive pulmonary fibrosis, which has a prognosis comparable to interstitial pulmonary fibrosis. In this study, relevant evidence about epidemiology, risk factors, biomarkers, and treatment are reviewed.</p></div><div><h3>Materials and methods</h3><p>A systematic review of the literature was carried out. Original observational and descriptive articles were included. Articles not providing information about the CTD diagnosis were excluded. PUBMED, EMBASE, SCOPUS, and LILACS were all searched. The total number of articles obtained was 528; data were extracted from 61 original articles.</p></div><div><h3>Results</h3><p>On average, ILD in these patients progressed by 33.7% over time. Patients with progressive pulmonary fibrosis had a similar 3.7-year median survival as those with idiopathic pulmonary fibrosis. Mortality was markedly increased (hazards ratio 3.29; 95% CI 2.76–3.82). A progressive course was seen in 34% of scleroderma (SSc) related ILD cases. Six interferon-induced proteins and a proteomic profile of 12 biomarkers were used to predict progression and response to treatment. The INBUILD and SENSCIS studies that assessed the effectiveness of nintedanib effectiveness revealed a reduced decrease in forced vital capacity. Progression in rheumatoid arthritis (RA) related ILD ranges from 38% to 50%. Control of RA disease activity and use of antifibrotics benefit the lungs.</p></div><div><h3>Conclusion</h3><p>A significant proportion of patients with CTD-ILD have progressive lung disease, with the corresponding adverse mortality effects. The majority of the data regarding CTD-ILD are from cohorts of patients with RA-ILD and SSc-ILD, in which antifibrotics and concurrent immunosuppressive treatments have been effective. There is not enough information available on other autoimmune disorders to draw any firm conclusions regarding progression rates or treatment effects.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 ","pages":"Pages S82-S93"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141091044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}